Feasibility of reversing benzodiazepine tolerance with flumazenil
@article{Savic1991FeasibilityOR, title={Feasibility of reversing benzodiazepine tolerance with flumazenil}, author={Ivanka Savic and Lennart Wid{\'e}n and Sharon Stone-Elander}, journal={The Lancet}, year={1991}, volume={337}, pages={133-137} }
86 Citations
Effects of flumazenil in the treatment of benzodiazepine withdrawal – a double-blind pilot study
- Psychology, MedicinePsychopharmacology
- 1997
There was an overall difference between patients and controls, with patients scoring higher on negative and somatic items and lower on positive psychological items, and flumazenil reduced symptoms thought to be important in withdrawal in patients treated for benzodiazepine dependency.
Pharmacology of flumazenil
- Medicine, PsychologyActa anaesthesiologica Scandinavica. Supplementum
- 1995
The existence of flumazenil is important, with implications for future research and the development of minimally invasive therapy and day‐case surgery, and with increasing pressures on non‐anaesthetically trained practitioners to perform sedation, it has important implications for safety.
Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo‐controlled study
- Medicine, PsychologyAddiction biology
- 2002
The effectiveness of FLU may reflect its capacity to upregulate BZD receptors and to reverse the uncoupling between the recognition sites of BzD and GABA, on the GABA A macromolecular complex, that has been reported in tolerant subjects.
Oral Flumazenil in the Treatment of Epilepsy
- Psychology, MedicineThe Annals of pharmacotherapy
- 1995
No adequately designed long-term trials have been conducted on treatment of epilepsy using flumazenil, rendering evaluation of its use as a single-agent antiepileptic difficult.
Benzodiazepine dependence and its treatment with low dose flumazenil
- Medicine, PsychologyBritish journal of clinical pharmacology
- 2014
Preliminary in vitro water bath and in vivo biocompatibility data in sheep show that such an implant is feasible and so is likely to be used in clinical trials in the near future, and could be capable of managing both acute and longer term benzodiazepine withdrawal sequelae.
A pilot study of the effects of flumazenil on symptoms persisting after benzodiazepine withdrawal
- Psychology, MedicineJournal of psychopharmacology
- 1992
The benefits last between a few hours and several days despite flumazenil's otherwise short duration of action, however, symptoms did return to varying degrees in most cases, suggesting the need for repeated doses.
Flumazenil-precipitated withdrawal in healthy volunteers following repeated diazepam exposure
- Psychology, MedicinePsychopharmacology
- 2004
These findings support previous human research studies indicating that flumazenil precipitates withdrawal after short chronic exposure to benzodiazepines and suggests that duration of exposure does not influence the intensity of withdrawal beyond the first week of exposure.
Benzodiazepine Receptor Antagonists
- Psychology, Medicine
- 1997
Flumazenil represents a promising tool for pharmacological investigations of the GABAergic system and for imaging of the benzodiazepine receptor, and as a neuronal marker in epilepsy and cerebral ischaemia.
Effectiveness of flumazenil (RO 15-1788) in the treatment of benzodiazepine withdrawal
- Psychology, Medicine
- 1993
In vivo studies on the mechanism of action of the broad spectrum anticonvulsant loreclezole
- Biology, PsychologyEpilepsy Research
- 1992
References
SHOWING 1-10 OF 24 REFERENCES
Rapid induction of lorazepam dependence and reversal with flumazenil.
- Psychology, BiologyLife sciences
- 1988
The anticonvulsant effect of the benzodiazepine antagonist, Ro 15-1788: an EEG study in 4 cases.
- Medicine, PsychologyEuropean neurology
- 1984
This investigation would suggest further study of Ro 15-1788 in epileptic patients for clarification of its anticonvulsant properties and evaluation of its action on the sedation caused by benzodiazepine antiepileptic medication is suggested.
Chronic benzodiazepine treatment decreases postsynaptic GABA sensitivity
- Biology, PsychologyNature
- 1984
Electrophysiological evidence for decreased postsynaptic sensitivity to GABA following chronic benzodiazepine administration is presented as measured by the direct iontophoretic application of GABA and serotonin onto serotonergic cells in the midbrain dorsal raphe nucleus (DRN), known to receive GABAergic input.
Spontaneous and RO 15-1788-induced reversal of subsensitivity to GABA following chronic benzodiazepines.
- Biology, PsychologyEuropean journal of pharmacology
- 1985
Precipitated withdrawal by a benzodiazepine receptor antagonist (Ro 15-1788) after 7 days of diazepam.
- Medicine, PsychologyScience
- 1982
Baboons implanted with intragastric catheters were given diazepam twice daily for 45 consecutive days and intramuscular injections of the benzodiazepine receptor antagonist Ro 15-1788 were given on days 7 and 35.
Convulsions induced by submaximal dose of pentylenetetrazol in mice are antagonized by the benzodiazepine antagonist Ro 15-1788.
- Biology, MedicineLife sciences
- 1983
Time course for development of anticonvulsant tolerance and GABAergic subsensitivity after chronic diazepam
- Biology, PsychologyBrain Research
- 1987
Benzodiazepine receptor occupancy in vivo: correlation with brain concentrations and pharmacodynamic actions.
- Medicine, BiologyThe Journal of pharmacology and experimental therapeutics
- 1987
The correlation between receptor occupancy and the pharmacodynamic actions of these drugs in blocking pentylenetetrazol seizures and inducing rotarod ataxia indicated that ED50 for these effects occurred at receptor occupancy of 30 to 60% for both drugs.
Audiogenic seizures in DBA/2 mice discriminate sensitively between low efficacy benzodiazepine receptor agonists and inverse agonists.
- Biology, PsychologyLife sciences
- 1983
Partial agonists of the benzodiazepine receptor: from animal data to results in patients.
- BiologyAdvances in biochemical psychopharmacology
- 1988
Concepts are presented here that could explain the modulatory function of the BZR, and a number of factors are proposed to determine the pharmacological and therapeutic profile of B zR ligands: intrinsic efficacy at the BzR, density of GABAA-BZR on neurons, functional reserve in GAB AA-BzRs, the intensity of the GABAergic input to a neuron, and the excitatory neuronal state.